Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage
Azhagu Madhavan Sivalingam, Arjun Pandian
Omicron variant raises global concerns: Increased hospitalization and India's vaccination advantage
The newly identified COVID-19 variant, B.1.1.529, initially detected in South Africa, was officially designated as the “Omicron” variant by the World Health Organization on November 26, 2021. This variant has raised concerns globally. From January 17 to November 26, 2021, Public Health Ontario (PHO) Library Services conducted extensive searches of published literature and preprints using the MEDLINE database. A total of six articles and one ongoing clinical trial were identified. Data from 15 published and unpublished reports, including interim findings, were collected. The WHO, ICMR, daily updates web page, internet sources, news, and hospitalization or death data were analyzed to assess the risk associated with the Omicron variant compared to non-hospitalized COVID-19 patients. The data suggested a potential 50% increase in the risk of hospitalization or death among Omicron patients compared to previous variants. Considering the emergence of the Omicron variant, it is important to note that India has an advantage due to its extensive immunization program, which annually vaccinates approximately 2.7 crorenewborns. However, it is crucial to ensure that vaccines meet all validation requirements and regulatory frameworks before they are made available to the public.
Omicron / South Africa / COVID-19,SARS-CoV-2 variant / AZ primary and mRNA booster
[1] |
Poudel S, Ishak A, Perez-Fernandez J, et al. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts-What is known so far? Trav Med Infect Dis. 2022; 45: 102234.
|
[2] |
Organization WH. WHO recommendations on mask use by health workers. In: Light of the Omicron Variant of Concern: WHO Interim Guidelines, 22 December 2021. World Health Organization; 2021.
|
[3] |
Kupferschmidt K. Where Did ‘weird' Omicron Come from? American Association for the Advancement of Science; 2021.
|
[4] |
Callaway E. Beyond Omicron: what's next for COVID's viral evolution. Nature. 2021; 600 (7888): 204- 207.
|
[5] |
Zahradník J, Marciano S, Shemesh M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021; 6 (9): 1188- 1198.
|
[6] |
Azhagu Madhavan S. Identification of Covid-19 Therapeutics and (Sars-Cov-2) Cluster Cases of India. 2021.
|
[7] |
Godlee F. Covid 19: why we need a global pandemic treaty. BMJ Br Med J (Clin Res Ed). 2021: 375.
|
[8] |
Burnett AL, Chang AG, Crone JK, Huang PL, Sezen SF. Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase. J Androl. 2002; 23 (1): 92- 97.
|
[9] |
Ahmad L. Implication of SARS-CoV-2 immune escape spike variants on secondary and vaccine breakthrough infections. Front Immunol. 2021: 4563.
|
[10] |
Callaway E. Heavily mutated coronavirus variant puts scientists on alert. Nature. 2021; 600 (7887): 21.
|
[11] |
Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019)- recent trends. Eur Rev Med Pharmacol Sci. 2020; 24 (4): 2006- 2011.
|
[12] |
Shoham S, Batista C, Ben Amor Y, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. eClinicalMedicine. 2023; 59: 101965.
|
[13] |
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022; 386 (15): 1397- 1408.
|
[14] |
Howard-Jones AR, Burgner DP, Crawford NW, et al. COVID-19 in children. II: pathogenesis, disease spectrum and management. J Paediatr Child Health. 2022; 58(1):46–53.
|
[15] |
Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009; 7 (6): 439- 450.
|
[16] |
Didović D, Nikčević A, Valenčak-Ignjatić I, Stemberger-Marić L, Roglić S. Covid-19 in children. Infektološki glasnik. 2021; 41 (1): 15- 21.
|
[17] |
Morawska L, Milton DK. It is time to address airborne transmission of coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020; 71 (9): 2311- 2313.
|
[18] |
Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020; 26 (4): 502- 505.
|
[19] |
Silverberg SL, Zhang BY, Li SNJ, et al. Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatr. 2022; 22 (1): 1- 13.
|
[20] |
Chen Feifan, Yan Tian, Zhang Lixin, Yuan Shi. The role of children in household transmission of COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022; 122: 266- 275.
|
[21] |
Fernandes Q, Inchakalody VP, Merhi M, et al. Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Ann Med. 2022; 54 (1): 524- 540.
|
[22] |
Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal Transduct Targeted Ther. 2022; 7 (1): 141.
|
[23] |
Imam MT, Almalki ZS, Alzahrani AR, et al. COVID-19 and severity of liver diseases: possible crosstalk and clinical implications. Int Immunopharm. 2023; 121: 110439.
|
[24] |
Hajikhani B, Safavi M, Bostanshirin N, et al. COVID-19 and coronary artery disease; A systematic review and meta-analysis. New Microbes New Infect. 2023; 53: 101151.
|
[25] |
Oh S, Seo H. Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines. Heliyon. 2023; 9 (5): e15668.
|
[26] |
Nemati Zargaran F, Rostamian M, Kooti S, Madanchi H, Ghadiri K. Co-infection of COVID-19 and parasitic diseases: a systematic review. Parasite Epidemiol. Control. 2023;21:e00299.
|
[27] |
Ye L, Fan S, Zhao P, et al. Potential herb-drug interactions between anti-COVID-19 drugs and traditional Chinese medicine. Acta Pharm Sin B. 2023. https://doi.org/10.1016/j.apsb.2023.06.001.
|
[28] |
Klomjit N, Zand L, Cornell LD, Alexander MP. COVID-19 and glomerular diseases. Kidney International Reports. 2023; 8 (6): 1137- 1150.
|
[29] |
Kanj SS, Haddad SF, Meis JF, et al. The battle against fungi: lessons in antifungal stewardship from COVID 19 times. Int J Antimicrob Agents. 2023; 62 (1): 106846.
|
[30] |
White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin Infect Dis. 2021; 73 (7): e1634- e1644.
|
[31] |
Chen W, Yin C, Zhong M, et al. Incidence and outcomes of patients with COVID-19 associated pulmonary aspergillosis (CAPA) in intensive care units: a systematic review and meta-analysis of 31 cohort studies. Ann Palliat Med. 2022; 11 (7): 2202- 2209.
|
[32] |
Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19- associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021; 21 (6): e149- e162.
|
[33] |
Kannan S, Ali PSS, Sheeza A. Evolving biothreat of variant SARS-CoV-2-molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021; 25 (12): 4405- 4412.
|
[34] |
Sariani OK, Dousari AS, Moghadam MT. Possible Psychological Consequences in Public of Omicron Variant (B. 1.1. 529) of SARS-CoV-2 Identification in Iran. 2022.
|
[35] |
MadhavanS, A.; Sripriya, R.; Priyadharshini, R., Medical and Healthcare Effective Therapeutic and COVID-19 Role of Herbal Medicine in the Treatment. Local Food and Community Empowerment through Tourism, 262.
|
/
〈 | 〉 |